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Introduction
Gold nanoparticles of various shapes have promising applications 
for the biomedical field [1-5]. Gold nanoparticles (NPs) have become 
a focus of interest in the fields of nanobiotechnology and biomedicine 
because of the ease of surface bioconjugation with molecular probes as 
well as remarkable optical properties related to the Localized Surface 
Plasmon Resonance (LSPR) [2,6-8]. LSPR of gold nanoparticles 
results in strong optical absorption and scattering at visible and near-
infrared wavelengths [6,9]. One type of gold nanoparticle with a strong 
tunable plasmon resonance in the near-infrared spectral range is the 
gold nanorod (GNR) [6]. GNR can absorb light about one thousand 
times more strongly than an equivalent volume of an organic dye 
[6,10]. Consequently, GNR have been employed in diagnostics [11], 
therapeutic-delivery systems [12], including small-molecule drugs 
[13] and exogeneous nucleic acids [14], imaging [15,16], sensing 
[17], and responsive advanced material assemblies [18]. Properties 
such as biocompatibility ease of functionalization, and near infrared 
optical imaging make gold nanorods promising in new theranostic 
platforms [4]. GNRs were also used as optoacoustic (OA) contrast 
agents for quantitative flow analysis in biological tissues [19] and to 
investigate the kinetics of drug delivery compounds [20] or contrasting 
imaging [16]. GNR stabilized with cetyltrimethylammonium bromide 
(CTAB) shows cytotoxicity [21]. To reduce CTAB cytotoxicity, gold 
nanoparticles in the solution are washed by centrifugation [22]. 
However, GNR require pegylation for in vivo, and many other types of 
applications where the CTAB layer is being replaced by poly(ethylene 
glycol). [21,22]. The modification of GNR is usually performed by 
adding poly(ethylene glycol) thiol (r-PEG-SH, or simply PEG) to the 
CTAB coated GNR solution, followed by the removal of the excess 
CTAB via dialysis or centrifugation [4,20,21,23,24]. The reasons 
for PEGylation of nanoparticle surface, i.e. the covalent attachment 
through thiol terminated PEG [25], includes shielding of antigenic 
and immunogenic epitopes, shielding receptor-mediated uptake by 
the Reticuloendothelial System (RES), and preventing recognition and 
degradation by proteolytic enzymes [26]. PEG-modified GNR showed 
a negative surface potential [22], as well as low level cytotoxicity in vitro 
[21], and can therefore be used for biomedical applications [27]. 
After intravenous administration, GNRs get distributed inside the 
body according to their modified affinity resulting in the enhancement 
of the targeted tissues [28]. The use of structurally modified GNR is 
less toxic to normal tissue during delivery. At the molecular level, 
GNR could traverse biologic barriers and preferentially accumulate 
in cancer cells [9, 29-31]. Targeting GNR to a specific site is a critical 
aspect of bioimaging when used as a contrast agent. It is also critical for 
achieving efficient photothermal therapy without side effects, especially 
after intravenous injection [32].
Methods for enhancing the accumulation in cells and tissues 
with strongly absorbing gold nanoparticles and gold nanorods were 
previously discussed [2,4,5]. The standard for conjugating antibodies 
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Abstract
Gold nanorods with a peak absorption wavelength of 760 nm were prepared using a seed-mediated method. A 
novel protocol has been developed to replace hexadecyltrimethylammonium bromide on the surface of the nanorods 
with 16-mercaptohexadecanoic acid and metoxy-poly(ethylene glycol)-thiol, and the monoclonal antibody HER2. The 
physical chemistry properties of the conjugates were monitored through optical and zeta-potential measurements to 
confirm surface chemistry changes. The efficiency of the modifications was quantified through measurement of the 
average number of antibodies per gold nanorod. The conjugates were investigated for different cells lines: BT-474, MCF7, 
MCF10, MDCK, and fibroblast. The results show successful cell accumulation of the gold nanorod HER2 conjugates 
in cells with HER2 overexpression. Incubation of the complexes in heparinized mouse blood demonstrated the low 
aggregation of the metallic particles through stability of the spectral properties, as verified by UV/VIS spectrometry. 
Cytotoxicity analysis with LDH release and MTT assay confirms strong targeting and retention of functional activity of 
the antibody after their conjugation with gold nanorods. Silver staining confirms efficient specific binding to BT-474 cells 
even in cases where the nanorod complexes were incubated in heparinized mouse blood. This is confirmed through in 
vivo studies where, following intravenous injection of gold nanorod complexes, silver staining reveals noticeably higher 
rates of specific binding in mouse tumors than in healthy liver. 
The conjugates are reproducible, have strong molecular targeting capabilities, have long term stability in vivo and 
can be used in pre-clinical applications. The conjugates can also be used for molecular and optoacoustic imaging, 
quantitative sensing of biological substrates, and photothermal therapy.
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to gold nanoparticles using covalent bonding was published by several 
research groups [1,4,33-35].
However, the conjugation processes are in need of improvement. 
Most protocols are hard to adapt to large-scale manufacturing of highly 
concentrated conjugates with strong affinity toward factors such as 
biochemical and physiological conditions of the cells and organs of the 
body [35].
In these studies, we adopted the published methodology of GNR 
fabrication [34,36,37] to get a high yield of narrow band GNR with 
optical absorption centered at 760 nm. The manufactured nanorods 
were pegylated and conjugated with monoclonal antibody (mAb) 
to become non-toxic as biocompatible agent. We characterized the 
conjugation efficiency of the monoclonal antibody (mAb) HER2/neu 
by measuring and comparing antibody binding of the GNRs before 
and after pegylation. We devised a novel protocol through reordering 
the steps involved in PEGylating GNR mAB conjugates for use in 
preclinical research with specific accumulation in tumors.
Materials and Methods
Reagents
The chemicals used in this study were purchased from the following 
companies: Hexadecyltrimethylammonium bromide (CTAB, Sigma), 
Gold(III) chloride trihydrate (HAuCl4·3H2O, Aldrich), Sodium 
Borohydride (NaBH4, Aldrich), Silver Nitrate (AgNO3, Sigma-Aldrich), 
Ascorbic Acid (Sigma), Potassium carbonate (K2CO3, Sigma- Aldrich), 
Poly (ethylene glycol) methyl ether thiol or Methoxypolyethylene glycol 
thiol mPEG thiol, MW 5000, (mPEG-Thiol or PEG, Laysan Bio Inc.), 
16-Mercaptohexadecanoic acid (MHDA, Sigma), Sodium Chloride 
(NaCl, Sigma), 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC, Pierce), N-hydroxysulfosuccinimide (sulfo-
NHS, Pierce), 2-(N-Morpholino) ethane sulfonic acid sodium salt 
buffer (MES, Sigma-Aldrich), Monoclonal antibody Herceptin (HER2, 
Genentech), trypan blue (Sigma), Phosphate buffered saline (PBS, 
Sigma), tris-buffered saline with Tween-20 (TBST, Dako, Denmark), 
target retrieval solution (TRS, Dako, Denmark).
Fabrication, PEGylation, conjugation of GNR, and 
characterization
We present below the details of a GNR fabrication protocol adapted 
from previously reported methodology [34,37, 38]. The base procedure 
is tailored to the needs of the specific experiments presented in this 
paper. It allows high-yield fabrication of a narrow size distribution of 
rods with a 760 nm plasmon resonance. In a typical procedure, 0.250 
ml of an aqueous 0.01 M solution of HAuCl4·3H2O was added to 7.5 ml 
of a 0.1 M CTAB solution in a test tube (15 ml glass tube). Then, 0.600 
ml of an aqueous 0.01 M ice-cold NaBH4 solution was added all at once. 
This seed solution was used 2-3 hours after its preparation. In the next 
step of the fabrication, exact proportions of 9.5 mL of 0.10 M CTAB, 
0.400 ml of 0.01 M HAuCl4·3H2O, and 0.060 ml of 0.01 M AgNO3 
solutions were added one at a time in the preceding order, then gently 
mixed by inversion. The solution at this stage appeared bright brown-
yellow in color. Then 0.064 ml of 0.10 M ascorbic acid was added. The 
solution became colorless upon addition and mixing of ascorbic acid. 
Ten minutes were allowed for the reaction to fully proceed before 
adding the required quantity of seed solution. The reaction mixture was 
gently mixed for 10 seconds and left undisturbed for 1-2 hours. Then, 
the solution was left under thermostatic conditions for 24 hours at the 
temperature of 30°C [1,37]. 
Before covalent binding with PEG, or conjugation with monoclonal 
antibody HER2, the GNR were centrifuged at low speed (1500 × g, 20 
min) for separation of unwanted aggregates like platelets and stars. 
Figure 1 shows UV-VIS absorption spectra of GNR. The first fraction 
comes from resuspension of the pellet after low speed centrifugation 
of the GNR-CTAB stock solution (not used in this report). The second 
fraction is from the supernatant which was used in all experiments. 
Spectra are normalized to match the short wavelength peak of the 
GNR-CTAB supernatant data. The GNR-CTAB complex is now ready 
for further modification. For pegylation [21,34], the GNR-CTAB 
solution was centrifuged at 14000 g for 10 minutes, the supernatant 
was removed, and the pellet was resuspended in Milli Q Water (MQW) 
to reduce the residual CTAB concentration to 0.01 M. Then, 1.0 ml 
of 2 mM K2CO3 was added to 8 ml of aqueous GNR solution and 1.0 
ml of 0.1 mM mPEG-Thiol (PEG). The resulting mixture was kept on 
a rocking platform at room temperature overnight. Excess PEG was 
removed from the solution by two rounds of centrifugation prior to 
final resuspension in PBS (pH 7.4).
For conjugation with monoclonal antibody, the general procedure 
replaces CTAB as described in the literature [21, 33] on the surface of 
GNR with MHDA for activation [34,38], monoclonal antibody (HER2, 
purified using desalting columns (Pierce Biotechnology, Rockford, IL) 
or a Microcon centrifugal filter device from Millipore), and PEG [21]. 
Figure 2 presents a schematic of the conjugation protocols investigated 
in this work. They differ by the order of the surface modification steps.
Protocol 1
The GNR-CTAB complex was resuspended in 1 ml of MQW. The 
GNR solution was then added to solutions of MHDA and PEG in molar 
ratio of 1 to 4 (or 2 mM and 8 mM respectively). This molar ratio was 
found experimentally: the optimal ratio was chosen as maximizing the 
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Figure 1: UV-VIS absorption spectra of GNR. First fraction is from resuspension 
of the pellet after low speed centrifugation of GNR-CTAB stock solution (not 
used in this report). The second fraction is from the supernatant which was use 
in all experiments. Spectra are normalized to match the short wavelength peak 
of the GNR-CTAB supernatant data.
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of binding with the antibody, while maintaining the plasmon 
resonance of the control (GNR-PEG). The spectra are presented in 
Figure 3: UV-VIS absorption spectra of GNR-Ab (HER2) conjugates 
with different modifications of GNR surface after incubation at 3 hours 
in 10% solution of FBS. Control sample is pegylated GNR (PEG). The 
other three samples are GNR modified with MHDA and PEG (molar 
ratios are 1, 2 and 4 MHDA for 8 PEG: 1M:8P, 2M:8P and 4M:8P, 
respectively), activated with cross linkers EDC and sulfo NHS (CL), 
then conjugated with Ab HER2.
The heterofunctional linker MHDA was added drop wise to GNR 
stock solution under mixing (2.5 µl of 2 mM MHDA for each 1 ml 
solution of GNR-CTAB, concentration 500 pM or ratio is 1:10000). 
After 60 min of mixing at RT, the GNR were exposed to a solution 
mPEG Thiol (2.5 µl of 8 mM PEG for each 1 ml solution of GNR-
MHDA: ratio is 1:40000) overnight as presented above and reported in 
the literature [21,34]. In our experience, this step can be significantly 
shortened with no noticeable ill effects. 4-6 hours at RT was found to be 
enough for efficient removal of CTAB.
This last step ensures filling the areas not covered by the 
heterofunctional MHDA, yielding well-shielded and stable particle 
surfaces. Before activation with EDC and sulfo NHS the GNR were 
purified by two rounds of centrifugation (12,000 × g, 15 min each), 
the supernatant was removed, and the pellet was resuspended in 1 ml 
of MQW. 10 µl of a mixture of EDC and sulfo-NHS were added from 
stock solution in MES buffer (0.1 M, pH 6.0) with 0.5 M NaCl in 10 mM 
and 0.4 mM concentrations, respectively. The resulting solution was 
gently agitated for 30 min at RT. The solution was again centrifuged 
at 12000 RPM for 10 minutes, the supernatant was removed and mAb 
HER2 was added to a final concentration of 100 μg/ml to 1 ml of 500 
pM activated GNR. This represents a ratio around 1000 between the 
number of Ab molecules and GNR. The mixture was incubated at RT 
for 1 hour and then left on a rocking platform overnight (+4oC). The 
final step was centrifugation of the solution of conjugates PEG-GNR-
mAb at 12000 g for 10 minutes. After resuspension, the pegylation step 
described above was repeated for 2 h at RT.
Then, the supernatant was removed and the pellet was resuspended 
in PBS (pH 7.4) and the conjugates were filtered through a 0.45 µm 
Millipore Express Plus membrane. The required concentration, 
determined from the molar extinction of our GNR (3.85 × 109 
M-1cm-1), was confirmed by optical density measurement and the 
spectral properties (UV-VIS spectra into range 400-1100 nm) were 
monitored by Beckman 530 or Thermo Scientific Evolution 201 
spectrophotometer[39]. 
Protocol 2
The second protocol (Protocol 2, Figure 2) was described before 
[33,34] but this work reports have slight modifications. For this, 
one ml of synthesized GNR in CTAB was centrifuged twice in a 1.5 
mL eppendorf tube at 14000 RPM for 15 minutes and resuspended 
in one mL of MQW to a concentration of 500 pM. Then, 10 µL of 5 
mM MHDA in ethanol was added to the GNR and the solution was 
sonicated for 30 minutes at 50°C to prevent aggregation. The solution 
was centrifuged at 12000 RPM for 10 minutes, the supernatant was 
removed, and the pellet was resuspended in MQW. 10 µl EDC and 
sulfo-NHS was added from stock solution in MES buffer in 10 mM 
and 0.4 mM concentrations, respectively. The mixture was sonicated 
for 30 minutes at room temperature (RT) to produce activated GNR 
(GNR that are capable of binding to the amine side chain of proteins). 
HER2 was added, at a final concentration of 100 μg/ml, to 1 ml of 500 
pM activated GNR just like in Protocol 1. The mixture was sonicated at 
RT for 30min and then left on a rocking platform overnight. Following 
the removal of excess HER2, 10 μl of PEG (1 mM) was added to 1 ml 
of GNR-HER2 conjugates and the mixture was incubated at room 
temperature for 12 h [34]. The solution of GNR-HER2-PEG conjugate 
was centrifuged at 12000 g for 10 minutes, the supernatant was 
removed and the pellet was resuspended in PBS pH 7.4 to a working 
concentration determined spectrophotometrically. 
Protocol 3
The third method of activation (Protocol 3) has the modification 
steps performed in another order (Figure2). Same one mL of 
synthesized GNR in CTAB was resuspended in one mL of MQW. 
MHDA was added to the GNR-CTAB solution, and the solution was 
sonicated for 30 minutes at 50°C to prevent aggregation. The solution 
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Figure 3: UV-VIS absorption spectra of GNR-Ab (HER2) conjugates with 
different modifications of GNR surface after incubation at 3 hours in 10% 
solution of FBS. Control sample is pegylated GNR (PEG). The other three 
samples are GNR modified with MHDA and PEG (molar ratios are 1, 2 and 
4 MHDA for 8 PEG: 1M:8P, 2M:8P and 4M:8P, respectively), activated with 
cross linkers EDC and sulfo NHS (CL), then conjugated with Ab HER2.
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was centrifuged at 12000 RPM for 10 minutes, the supernatant was 
removed and the pellet was resuspended in MQW. At the same time a 
complex of mAb and crosslinkers was prepared from mAb and solution 
of EDC/sulfo NHS in MES buffer. The compound was agitated at RT 
for 30 min. The activated mAb was purified by centrifugation with 3000 
kDa membrane (possible use dialysis), and additional washing by salt 
column (Pierce). The clean complex was added to the GNR-MHDA 
solution and left overnight (4oC). Following the removal of excess mAb 
by centrifugation, the GNR-mAb complex was pegylated as shown in 
Protocol 2. The resulting solution of GNR-mAb-PEG conjugate was 
centrifuged at 12000 g for 10 minutes, the supernatant was removed and 
the pellet was resuspended in PBS pH 7.4 to a working concentration 
determined spectrophotometrically.
The zeta-potential of GNR before and after formation of different 
conjugates was measured with a high performance particle sizer 
(Malvern Instruments Ltd., Southborough, MA, USA) at 25°C, and ten 
20-second runs were performed for each sample [39,40]. Zeta-potential 
is a measure of both particle stability and adhesion. More negative or 
positive values of zeta-potential are associated with more stable particle 
solution, because repulsion between the particles reduces the particle 
aggregation [38,40]. (Figure 4) Zeta-Potential (mV) for CTAB coated 
GNR stock solution (CTAB), GNR after PEGylation (PEG), GNR 
after removed CTAB with MHDA and PEG (MHDA-PEG) and three 
different protocols for conjugation and pegylation. GNR with MHDA 
and PEG, activated with cross linkers EDC and sulfo NHS (CL) and 
conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR with 
MHDA, activated with CL, conjugated with Ab and pegylated: GNR-
MHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated with 
Ab CL complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot 3) 
(mean ± SEM, n = 10-14 for each conjugate).
A measure of total and bound protein (HER2) was performed 
with the Pierce Micro BCA™ Protein Assay Reagent Kit (Pierce). 
Concentration of HER2 was measured before, and after addition 
of GNR-activated solution: it is dependent upon either the level of 
monoclonal antibody, or incubation time. Figure 5 shows Mean 
number of HER2 molecules on the surface of GNR after conjugation 
through different protocols (synthesis steps for protocol 1, 2 and 3 
are the same as in Figure 4). As negative control we used solutions of 
antibody without GNR. The determination was performed through 
measurement of absorbance at or near 562 nm by Cary 500 UV-VIS-
NIR spectrophotometer [38]. It is important to note that the ratio of 
absorbance at 562 nm (proteins relative to BSA) has a coefficient of 
variation of only around 10% [39].
Cell culture, viability and cell proliferation 
Cell lines BT 474 (Human breast distal carcinoma with HER2 
receptor overexpression), MCF 7 (Human breast adenocarcinoma with 
HER2 receptor overexpression), MCF 10A (Human breast fibrocystic 
disease, no HER2 receptor overexpression), MDCK (normal dog kidney 
epithelial cells), and Human lung normal fibroblast were obtained from 
American Type Culture Collection (ATCC) and cultured in essential 
media with 10% fetal bovine serum.
Cell viability (Figure 6) was determined using the Cytotoxicity 
Detection Kit which measures cytotoxicity by detecting lactate 
dehydrogenase (LDH) activity released from damaged cells (Roche). It 
was described in our previous works [40,41]. 
Cell survival following GNR conjugates incubation at different 
concentrations (50-500 pM) was monitored. BT 474 cells were seeded 
into a 96-well plate at a density of 2×105 cells/ml in 0.1 ml of media per 
well. 3 hours before treatment, media were changed to 0.1 ml of low 
serum (0.5%). 0.025 ml of GNR conjugates were added in low serum 
media too. After 48 h of incubation with GNR conjugates, the 25 µl 
samples of media were collected for measurement of LDH release from 
the cells [40,41].
The proliferation of viable cells was determined by examining the 
conversion of MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide, a tetrazole] to a purple formazan product by meta-
bolically active cells using a kit (Roche). BT 474 cells were used in the 
same plate (after removing the 25 µl of media for LDH assay) and the 
MTT assay was performed on the pretreated plate with different GNR 
cells. Absorbance of the LDH and MTT products was measured on a 
plate spectrophotometer (Bio-Tek Instruments, Inc.). Data for LDH 
release, MTT assay and LDH/MTT ratios, were measured and calculat-
ed from 4–6 replicates. Figure 7 summarizes the results: Metabolically 
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Figure 4: Zeta-Potential (mV) for CTAB coated GNR stock solution (CTAB), 
GNR after PEGylation (PEG), GNR after removed CTAB with MHDA and PEG 
(MHDA-PEG)  and three different protocols for conjugation and pegylation. 
GNR with MHDA and PEG, activated with cross linkers EDC and sulfo 
NHS (CL) and conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR 
with MHDA, activated with CL, conjugated with Ab and pegylated: GNR-
MHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated with Ab CL 
complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot 3)  (mean ± SEM, 




















Figure 5: Mean number of HER2 molecules on the surface of GNR after 
conjugation through different protocols (synthesis steps for protocol 1, 2 and 3 
are the same as in Figure 4). 
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and MTT following incubation of BT 474 cell with GNR conjugates for 
48 h, at concentrations up to 500 pM (or 3 × 1011 GNR/ml). Synthesis 
steps for protocols 1, 2 and 3 are the same as in Figure 4 (mean ± SD, 
n = 6 independent measures for each conjugate). All protocols show 
significant level of cell death, from Prot 1 (highest) to Prot 3 (lowest).
The other technique to assess cell viability is based on trypan blue 
(Sigma) dye exclusion [40]. This staining was used for investigation of 
cell viability of BT 474, MCF 7, MCF 10 and MDCK cells as well as 
for measuring surviving these cells their after incubation with GNR-
PEG, and conjugates from protocols 1, 2 and 3 (all at 500 pM or 3 × 
10 11 GNR/ml, 48 h, n = 6, M±SD). After this, the cells were incubated 
5 min with 0.4% trypan blue, and counted as a percentage of stained 
cells to total number of cells. As positive control, we used cells to which 
only PBS solution (pH 7.4, at 25°C) was added. Correspondingly, 
knowingly toxic CTAB-coated GNR solutions [16] were added in the 
same concentrations as GNR conjugates and these samples were used 
as negative controls in each experimental condition.
This thorough comparative study had been devised in order to 
compare the GNR conjugates fabricated with 3 different protocols, and 
assess their relative performance. After confirming suitability, the novel 
order of conjugation (Protocol 1) was chosen for all in vitro and in vivo 
experiments related to the visualization of receptors and distribution 
on GNR conjugates in tumor and liver tissue. 
Optical visualization of binding of GNR conjugates with BT 474 
cells and fibroblasts was performed through the use of a silver staining 
kit (SS, BBI International, UK) according to manufacturer instructions. 
Cells with (BT 474) and without (Fibroblasts) overexpression of 
HER2 receptors were treated with GNR HER2 conjugates. Incubation 
time of GNR conjugates was 1 h. GNR conjugates were pretreated 
with heparinized mouse blood (preincubation time is 4 h). Optical 
visualization of HER2 receptors was performed after fixation of cells 
with a mixture of formaldehyde (2.5%) and glutaraldehyde (1.5%). 
Figure 9 shows Silver staining of fibroblast (no HER2/neu expression) 
and BT-474 cells following 60 min pre-treatment with pegylated (GNR-
PEG) or conjugated through protocol 1 (GNR-PEG-HER2) GNR 
which were incubated with heparinized mouse blood for four hours. 
BT 474 shows silver enhancement for GNR-PEG-HER2 conjugates in 
both conditions: before and after incubation of GNR-conjugates with 
blood.
Animal studies for optical and optoacoustic imaging
For investigation of GNR HER2 conjugates distribution we used 
(animal models) mice with tumors that overexpressed HER2/neu 
receptor. In vivo experiments aimed to evaluate whether GNR HER2 
conjugates are accumulated within tumors that overexpress HER2/
neu receptor in the same as in other animal model tissue without 
overexpression of this receptor. We used Athymic Nude-Foxn1nu 
mice (Harlan), 7-9 weeks old, weighing about 25 g. Animal handling, 
GNR conjugates injections, and euthanasia were described in detail 
in our publications [15,16] and each mouse-related procedure was in 
compliance with our Institutional Animal Care and Use Committee 
(IACUC) protocol. This model was made through BT474 cells injection 
(2 × 106), subcutaneously in the flank area of nude mice [34]. The 
tumors had a diameter of 4-6 mm after three-four weeks. 
The mice had 200 µl of GNR conjugates in sterile PBS injected 
intravenously (IV) through the tail vein. The injected solution 
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Figure 6: Fraction of dead cells for the cell lines (BT 474, MCF 7, MCF 10 
and MDCK) after incubation with GNR HER2 conjugates for 48 h, 250 pM 
(or 1.5 × 1011 GNR/ml). The number of dead cells was counted after staining 
with Trypan Blue. Control groups of cells received treatment with PBS or GNR 
after PEGylation (PEG). Synthesis steps for protocols 1, 2 and 3 are the same 
as in Figure 4 (mean ± SD, n=6 independent measures for each conjugate). 
Results indicate significantly higher level of cell death for cells with HER2/neu 
expression, BT 474 and MCF7, and no significant changes without HER2/neu 
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Figure 7: Metabolically active cells (MTT assay), LDH release, and ratio 
between LDH release and MTT following incubation of BT 474 cell with GNR 
conjugates for 48 h, at concentrations up to 500 pM (or 3 × 1011 GNR/ml). 
Synthesis steps for protocols 1, 2 and 3 are the same as in figure 4 (mean 
± SD, n=6 independent measures for each conjugate). All protocols show 
significant level of cell death, from Prot 1 (highest) to Prot 3 (lowest).
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150 pM after distribution within the mouse’s body. Selected mice were 
sacrificed at 48 h after the IV injections of GNR conjugates. Tissues of 
liver and tumor extractions were produced as paraffin-imbedded slices 
for Silver Staining (SS) and Hematoxylin Eosin (H&E) staining. Tissue 
sections (5 µm) were deparaffinized and rehydrated through xylene (3 
changes, 5 min each) and graded ethanol solutions from 100 to 50% 
(1 min each). After this, samples were rinsed in dH2O and placed in a 
water bath for 10 min with tris-buffered saline with Tween 20 (TBST, 
Dako, Denmark). Retrieval with Target Retrieval Solution pH 6.1 
(TRS, Dako, Denmark) was then performed in a preheated container 
at 96-99°C for 30-40 min. The slides of liver sections were stained for 
PEG-GNR optical visualization with a SS Kit (BBI International, UK) 
according to manufacturer instructions, and HE stained for analysis 
of possible pathological consequences in liver after GNR conjugates 
administration. The results are shown in Figure 10 Above: Hematoxylin 
& Eosin (tumor and liver), and below: silver staining (tumor and liver) 
of GNR accumulated in mouse tissues following intravenous injection 
of PBS, GNR-PEG or GNR-PEG-HER2 conjugates. Silver staining 
shows that GNR peg or Ab conjugates have uniform distribution in 
liver tissue and noticeably higher numbers of GNR specific conjugates 
in mouse tumors. 
Result and Discussion
We evaluated the protocol that improves the conjugation process of 
mAb to GNR and enhances GNR activity toward targeting antibodies. 
A significant part of this evaluation consists in the purification of 
GNR-CTAB stock solution. After low speed centrifugation of the stock 
solution, the pellet containing mostly platelets, stars, and other non-
rod-like particles was discarded and only the supernatant was used 
as clean solution of GNR in different modification and conjugations 
procedures (Figure 1). In this study we compare three different 
protocols of activation and conjugation of GNR with mAb (Figure 2).
The optimized method of activation of GNR differs by the order 
of the modification steps (Protocol 1 on Figure 2). The GNR-CTAB 
MQW solution is mixed with MHDA and PEG (in molar ratio 1:4), 
and activated though EDC and sulfo-NHS as the complex PEG-GNR-
MHDA. This complex is capable of conjugation through the carboxy 
group of MHDA for binding with an amine function of proteins, 
antibody or peptides [4,18]. Optimization of the ratio between MHDA 
and PEG was investigated by UV-VIS absorption spectra of GNR-Ab 
(HER2) conjugates with different modifications of GNR surface after 
incubation at 3 hours in 10% solution of FBS (Figure 3). Conjugated 
HER2 on the surface modified with MHDA and PEG was more stable 
at 1 and 2 molar parts of MHDA for 8 parts of mPEG thiol. Due to the 
two fold increase in number of binding sites with similar stability in 
FBS solution, our choice was 1:4 molar ratio. This type of conjugation 
has not shown significantly different spectral behavior from pegylated 
GNR.
To confirm the chemistry modification of GNR-PEG conjugates we 
investigated the Zeta-potential (Figure 4). It was measured for CTAB 
coated GNR stock solution (CTAB), GNR after PEGylation (PEG), 
GNR after CTAB removal with MHDA and PEG (MHDA-PEG) and 
three different protocols for conjugation and pegylation. GNR with 
MHDA and PEG, activated with cross linkers EDC and sulfo NHS (CL) 
and conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR 
with MHDA, activated with CL, conjugated with Ab and pegylated: 
GNR-MHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated 
with Ab CL complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot 
3). The zeta-potential (Figure 4) of the GNR-CTAB complex was highly 
positive due to the presence of the positively charged CTAB molecules. 
After PEGylation, a negative zeta-potential confirmed chemistry 
changes to the GNR surface: the CTAB bi-layer was removed (Figure 
4). The GNR HER2 conjugates solution showed a zeta-potential which 
is slightly negative, but significantly different from zero. Zeta potential 
changes do confirm surface chemistry modifications, and correspond 
to previously published data [40,42].
Investigation of binding of mAb (HER2) on the surface of activated 
GNR is presented in Figure 5 for all the protocols. Comparison of the 
different protocols of conjugation with number of HER2 molecules on 
the surface of GNR after conjugation shown that Protocol 1 yields the 
highest density of HER2 on the surface of GNR.
We investigated the influence of concentrations of GNR-PEG 
conjugates on the physiological status of cell cultures for different 
protocols of GNR conjugations (Figure 6). The cells of four lines (BT 
474, MCF 7, MCF 10 and MDCK) were incubated with GNR HER2 
conjugates for 48 h, at 250 pM (or 1.5 × 1011 GNR/ml). The number of 
dead cells was counted after staining with Trypan Blue [43]. Control 
groups of cells received treatment with PBS or GNR after PEGylation 
(PEG). Results indicate significantly higher level of cell death for cells 






















PEG      Prot1      Prot2       Prot3

















Figure 8: UV-VIS absorption spectra of supernatant solutions of GNR-Ab 
(HER2) conjugates after incubation for six hours in heparinized mouse blood. 
Synthesis steps for protocols 1, 2 and 3 are the same as in figure 4. Before 
and after 1 h incubation all protocols for conjugated and pegylated (PEG 
and Prot. 1, Prot. 2 and Prot. 3, respectively) have similar spectra. After 6 h 
incubations a higher level of aggregation is observed in samples from Prot 3, 
with the best results for Prot.1 (lower aggregation)
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of cell death can be seen for the cell lines without HER2/neu expression: 
MCF 10 and MDCK. Following GNR-CTAB administration, the level 
of dead cells was 4-5 times higher in comparison with GNR conjugates 
and did not show differentiation between groups of cells (data not 
presented).
Dose dependence response from BT 474 (overexpressed of HER2 
receptors) was investigated by MTT assay, LDH release from the cell 
into the media, and ratio between LDH release and MTT following cell 
incubation with GNR conjugates for 48 h, at concentrations up to 500 
pM (Figure 7). All protocols show significant level of cell death, which 
corresponds to ratio of LDH by MTT [16,44]. However consequences 
for cell’s, cell death was higher from Protocol 1 conjugates and lowest 
from Protocol 3.
Figure 8 shows UV-VIS absorption spectrum of supernatant 
solutions of GNR-Ab (HER2) conjugates after incubation for six 
hours in heparinized mouse blood. Before and after 1 h incubation. 
All protocols for conjugated and pegylated (PEG and Prot. 1, Prot. 2 
and Prot. 3, respectively) have similar spectra. After 6 h incubation 
period, the pegylated sample shows little change, but a higher level of 
aggregation is observed in the conjugated samples, the highest from 
Protocol 3, and the lowest (best) results for conjugates from Protocol 
1. This type of conjugate is more stable, resulting in an absorption peak 
around that of the control pegylated GNR, and can thus maintain the 
plasmon resonance in the biological transparency window for longer 
times [6,21].
Comparative studies confirmed suitability of the novel order of 
conjugation steps, therefore Protocol 1 was used for experiments 
related to the characterization of specific targeting of GNR HER2 
conjugates with cells in vivo application. 
The incubation of GNR-PEG-HER2 conjugates with BT 474 and 
fibroblasts has shown to selectively bind to cancer cells after they are 
incubated in blood (Figure 9). GNR conjugates were incubated with 
heparinized mouse blood for 4 h and then were incubated with both 
BT-474 cells as well as fibroblasts for 30 min at 37°C. The cell plates 
were rinsed with PBS to remove unattached GNRs, and the plates 
were stained using silver enhancement kit. Figure 9 shows a significant 
increase in the number of GNR conjugates on the cells surface only for 
selective binding to BT-474 cells that overexpress HER2/neu receptor, 
but for both experimental conditions: before and after pre incubation 
of conjugates with blood. Fibroblasts do not have overexpressed HER2/
neu receptors and silver staining cannot visualize GNR conjugates 
on the cell surface. GNR conjugates were added to the media at 
a concentration of 500 pM. This concentration is consistent with 
reported levels of GNR-PEG in blood or tissue after IV administration 
in vivo (12, 22, 23 ml). Results from these experiments are very similar 
to data previously published for methods of conjugation similar to 
Protocol 2 [34]. However, the novel method is much easier to perform, 
less time-consuming and provides a higher yield of conjugated GNR.
In vivo GNR conjugate administration has aimed to evaluate specific 
accumulation within tumors that overexpress HER2/neu receptors in 
animal models. Figure 10 shows results from an experiment in which 
GNR-PEG-HER2 complexes were found to accumulate within tumors 
and the liver of animals. 48 hours post tail vein injection, mice were 
sacrificed and samples of tumor and liver were stained with H&E and 
SS (Figure 10). One group of mice was injected by GNR-PEG-HER2 
conjugate, and another with pegylated GNR (GNR-PEG). One mouse 
was used as a control and thus was injected with only PBS. HE staining 
(above) and SS (below) show different cases of GNR accumulated 
in mouse tissue following intravenous injection of PBS, GNR-PEG 
or GNR-PEG-HER2 conjugates. HE staining did not show a visible 
difference between the PBS control and the GNR slices of liver tissue 
after IV administration of GNR-PEG conjugates (Figure 10). The 
results are consistent with those reported by other groups [32,45] 
for similar dosage of GNR (around 10-20 mg/kg body mass), and are 
presented solely as confirmation our GNR-PEG complexes are non-
toxic. Silver staining shows that GNR PEG or Ab conjugates have 
uniform distribution in liver and noticeably higher number of GNR 
specific conjugates in mouse tumor. 
We present SS data showing the accumulation of PEG-GNR and 
GNR-HER2 into liver Kupffer cells in comparable concentration, 
as this is not related to selective binding: these cells are specialized 
macrophages located in the liver and lining the walls of the sinusoids, 
and are responsible for removing non metabolized compounds from 
the organism. They are an important part of the reticuloendothelial 
system [26]. 
We used GNR conjugates for IV administration in same dose as 
we studied for enhancement of optoacoustic imaging pegylated GNR: 
PBS                    GNR-PEG           GNR-PEG-mAb
Fibroblasts + GNR Before Incubation with  Blood
BT 474 + GNR Before Incubation with  Blood
BT 474  + GNR After Incubation with Blood
Fibroblast  + GNR After Incubation with Blood
Figure 9: Silver staining of fibroblast (no HER2/neu expression) and BT-474 
cells following 60 min pre-treatment with pegylated (GNR-PEG) or conjugated 
through protocol 1 (GNR-PEG-HER2) GNR which were incubated with 
heparinized mouse blood for four hours. BT 474 shows silver enhancement for 
GNR-PEG-HER2 conjugates in both conditions: before and after incubation of 
GNR-conjugates with blood.
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around 20 mg/kg/BW [15,16] we believe that specific binding can 
significantly improve medical imaging.
Discussion and Summary 
Currently, conjugation of biomolecules to gold nanorods can be 
divided into four different methodologies: the use of a biofunctional 
linker which binds to gold at one end and to biomolecules on the 
other end, direct ligand exchange of the CTAB capping molecules 
with the biomolecules, functionalized coating of molecules that are 
electrostatically adsorbed onto the capping molecules while binding to 
biomolecules at their sites of functional groups, and electrostatically 
adsorbed onto the capping molecules [18].  
The thiol exchange is the most common way to replace the original 
capping molecules since the metal–sulfur bond is known to be the 
strongest bond among different functional groups: amines, carboxylic 
acids, alcohols, and phosphors [18]. 
Biomolecules such as PEG, [9,21] DNA, [14,46], lipids [47] 
and small molecular ligands for cellular biomarkers, [48] are first 
functionalized with an alkythiolated linker and then bound to GNR 
through Au–S bonds after few hours of reaction [18]. 
For some biomolecules, such as antibodies and proteins, thiolation 
is complicated by the fact that molecules are too large to reach the 
gold surface due to the dense packing of the CTAB double layers. 
The use of small bifunctional molecules such as 3-mercaptopropionic 
acid (MPA), 11-mercaptoundecanoic acids (MUDA), and 
16-Mercaptohexadecanoic acid (MHDA) [34,38,49,50] and cystamine 
[51] are useful in these studies. These small bifunctional molecules are 
very similar to bifunctional PEG. 
Biocompatible and nontoxic nanoparticles have been used 
for in vivo tumor targeting and detection based on pegylated gold 
nanoparticles and surface-enhanced Raman scattering [52]. This team 
used two different molecules of PEG, carboxy PEG thiol (3000 Da) for 
mAb bonding and PEG thiol (500 DA) for preventing recognition and 
degradation by proteolytic enzymes uptake by the RES. Our preliminary 
study demonstrated that MHDA with pegylation is preferred for 
prevention of aggregation of GNR conjugates in solutions of BSA or 
FBS. The method of bifunctional linkage is easier, faster, and more 
efficient, in comparison with other methods of removal of CTAB and 
along with pegylation can be successfully used for long-time storage 
(two-three month) or in vivo application. Additionally, this method 
made better masks against recognition of GNR conjugates for in vivo 
application, because the “bridge” MHDA-zero size linker (EDC-NHS)-
mAb is comparable in size (length) as PEG thiol 5000. Furthermore, the 
functional activity of Ab is not lost upon conjugating. Accumulation 
of GNR conjugates in regions of interest can form a base for contrast 
enhancements in many applications such as optical imaging, opto- and 
photo- acoustic imaging, optical coherent tomography, thermotherapy 
and thermolysis, drug delivery and monitoring, as well as sensing.
In summary, we demonstrated that a combination of pegylation 
before conjugating GNR with mAb provided nontoxic GNR-PEG-
HER2 conjugates with stable plasmon resonance suitable for in vitro 
and in vivo applications. We successfully optimized a protocol for 
fabrication of GNR conjugates to be suitable as in vivo contrast agent. 
We have shown the optimal molar ratio between short functionalized 
molecules used as bridges for linkers, and methoxy PEG thiol was 
around 1 to 4. During the conjugation step, the optimum ratio between 
activated GNR and number of molecules of mAb is around 1000. These 
ratios can be used for many biomolecules for conjugation with GNR 
for biomedical applications.
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